유전성 혈관부종 시장 - 세계 및 지역별 분석 : 치료 유형별, 지역별 - 분석 및 예측(2025-2035년)

Market Lifecycle Stage

The global hereditary angioedema market is currently in the growth stage of its lifecycle. This phase is characterized by an increasing number of treatment options, including novel biologic therapies and prophylactic treatments, which are gaining regulatory approvals. The market is experiencing expansion driven by the rising awareness of hereditary angioedema, improved diagnostic methods, and the introduction of advanced therapies such as C1 esterase inhibitors and bradykinin receptor antagonists. Additionally, the growing focus on personalized medicine and preventive care is contributing to the growth of the market. Although challenges such as high treatment costs and a limited patient population remain, the ongoing innovation in treatment options and expanding market access are expected to sustain the market's growth in the coming years.

Impact

• Increasing demand for hereditary angioedema therapies is anticipated to support the growth of the global hereditary angioedema market during the forecast period 2025-2035.
• The global hereditary angioedema market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers.

Market Segmentation:

Segmentation 1: by Therapy Type

• C1-esterase inhibitor
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor
• Others

Segmentation 2: by Region

• North America
• Europe
• Asia-Pacific

North America is expected to dominate the global hereditary angioedema market during the forecast period due to its advanced healthcare infrastructure, high prevalence, and increased awareness of the disease. The region also benefits from regulatory advantages and a strong pharmaceutical presence, which accelerates the availability of effective treatments and drives the growth of the global hereditary angioedema market.

Recent Developments

• Regulatory Activities: In February 2025, EMA approved an additional 2 mL pre-filled pen option for TAKHZYRO (lanadelumab) for subcutaneous administration in adolescents (aged 12 years and above) and adult patients with hereditary angioedema (HAE).
• Regulatory Activities: In February 2025, CSL Behring secured regulatory approval in Japan for Andembry (garadacimab) subcutaneous injection 200mg Pens for the prevention of acute hereditary angioedema attacks.
• Regulatory Activities: In January 2025, Japan's Ministry of Health, Labour and Welfare (MHLW) granted Orphan Drug Designation to KalVista Pharmaceuticals, Inc.'s sebetralstat.
• Regulatory Activities: In November 2024, the FDA accepted the new drug application for Ionis Pharmaceuticals' donidalorsen for the prophylactic treatment of hereditary angioedema.

Demand - Drivers and Limitations

The following are the drivers for the global hereditary angioedema market:

• Increasing Awareness and Early Diagnosis
• Continuous Advancements in Treatment Options
• Improved Genetic Testing and Diagnosis
• Increasing Prevalence of Hereditary Angioedema

The global hereditary angioedema market is expected to face some limitations, too, due to the following challenges:

• High Treatment Costs
• Challenges in Accessing Treatments in Developing Regions

How Can This Report Add Value to an Organization?

Product/Innovation Strategy: Product launches and innovations in the global hereditary angioedema market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the market, such as Ionis Pharmaceutical, Takeda, and CSL Behring, have been involved in the development of therapies for hereditary angioedema.

Competitive Strategy: Enterprises led by market leaders in the global hereditary angioedema market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and by analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

• Adverum Biotechnologies, Inc.
• Attune Pharmaceuticals
• BioCryst Pharmaceuticals
• CSL Behring
• Ionis Pharmaceuticals, Inc.
• KalVista Pharmaceuticals
• Octapharma
• Pharming Group
• Takeda Pharmaceutical Company Limited

Table of Contents

Executive Summary

Scope of Study

1. Global Hereditary Angioedema Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Market Trends
• 1.3 Epidemiological Analysis of Hereditary Angioedema
  • 1.3.1 By Region
• 1.4 Clinical Trials
  • 1.4.1 By Phase
  • 1.4.2 By Sponsor Type
• 1.5 Regulatory Landscape / Compliance
  • 1.5.1 Legal Requirement and Framework in the U.S.
  • 1.5.2 Legal Requirement and Framework in the E.U.
  • 1.5.3 Legal Requirement and Framework in Asia-Pacific
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Restraints
  • 1.6.4 Market Opportunities

2. Global Hereditary Angioedema Market, By Therapy Type, $Million, 2023-2035

• 2.1 C1-esterase inhibitor
• 2.2 Bradykinin B2 receptor antagonist
• 2.3 Kallikrein inhibitor
• 2.4 Others

3. Global Hereditary Angioedema Market, By Region, $Million, 2023-2035

• 3.1 North America
  • 3.1.1 Market Dynamics
  • 3.1.2 Market Sizing and Forecast
    • 3.1.2.1 North America Hereditary Angioedema Market (by Country)
      • 3.1.2.1.1 U.S.
• 3.2 Europe
  • 3.2.1 Market Dynamics
  • 3.2.2 Market Sizing and Forecast
    • 3.2.2.1 Europe Hereditary Angioedema Market (by Country)
      • 3.2.2.1.1 U.K.
      • 3.2.2.1.2 Germany
      • 3.2.2.1.3 France
      • 3.2.2.1.4 Italy
      • 3.2.2.1.5 Spain
• 3.3 Asia-Pacific
  • 3.3.1 Market Dynamics
  • 3.3.2 Market Sizing and Forecast
    • 3.3.2.1 Asia-Pacific Hereditary Angioedema Market (by Country)
      • 3.3.2.1.1 Japan

4. Global Hereditary Angioedema Market - Competitive Benchmarking and Company Profiles

• 4.1 Competitive Landscape
  • 4.1.1 Key Strategies and Developments by Company
    • 4.1.1.1 Funding Activities
    • 4.1.1.2 Mergers and Acquisitions
    • 4.1.1.3 Regulatory Approvals
    • 4.1.1.4 Partnerships, Collaborations and Business Expansions
  • 4.1.2 Key Developments Analysis
• 4.2 Company Profiles
  • 4.2.1 Takeda Pharmaceutical Company Limited
    • 4.2.1.1 Company Overview
    • 4.2.1.2 Product Portfolio
    • 4.2.1.3 Target Customers/End Users
    • 4.2.1.4 Analyst View
  • 4.2.2 CSL Behring
    • 4.2.2.1 Company Overview
    • 4.2.2.2 Product Portfolio
    • 4.2.2.3 Target Customers/End Users
    • 4.2.2.4 Analyst View
  • 4.2.3 Ionis Pharmaceuticals, Inc.
    • 4.2.3.1 Company Overview
    • 4.2.3.2 Product Portfolio
    • 4.2.3.3 Target Customers/End Users
    • 4.2.3.4 Analyst View
  • 4.2.4 Pharming Group
    • 4.2.4.1 Company Overview
    • 4.2.4.2 Product Portfolio
    • 4.2.4.3 Target Customers/End Users
    • 4.2.4.4 Analyst View
  • 4.2.5 BioCryst Pharmaceuticals
    • 4.2.5.1 Company Overview
    • 4.2.5.2 Product Portfolio
    • 4.2.5.3 Target Customers/End Users
    • 4.2.5.4 Analyst View
  • 4.2.6 KalVista Pharmaceuticals
    • 4.2.6.1 Company Overview
    • 4.2.6.2 Product Portfolio
    • 4.2.6.3 Target Customers/End Users
    • 4.2.6.4 Analyst View
  • 4.2.7 Attune Pharmaceuticals
    • 4.2.7.1 Company Overview
    • 4.2.7.2 Product Portfolio
    • 4.2.7.3 Target Customers/End Users
    • 4.2.7.4 Analyst View
  • 4.2.8 Adverum Biotechnologies, Inc.
    • 4.2.8.1 Company Overview
    • 4.2.8.2 Product Portfolio
    • 4.2.8.3 Target Customers/End Users
    • 4.2.8.4 Analyst View
  • 4.2.9 Octapharma
    • 4.2.9.1 Company Overview
    • 4.2.9.2 Product Portfolio
    • 4.2.9.3 Target Customers/End Users
    • 4.2.9.4 Analyst View

5. Research Methodology